Efficacy of isoflavones in relieving vasomotor menopausal symptoms - A systematic review.
This review assessed the efficacy of isoflavone supplements to reduce vasomotor symptoms in menopausal women by reviewing all published randomized controlled trials. Systematic literature searches were carried out in 70 databases. Randomized and placebo controlled studies were included if they investigated the treatment of isoflavone supplements derived from soy or red clover on vasomotor symptoms in peri- or postmenopausal women for at least 12 wks. Data were analyzed concerning outcome and methodological quality of the study. Twenty-three trials met the inclusion criteria, thereof 17 investigated soy isoflavones and 6 red clover isoflavones. Without exception, selected trials examining the effect of red clover isoflavones were already assessed in several meta-analyses and were therefore excluded from this evaluation. As the soy isoflavone studies were very heterogeneous concerning interventions and outcome measures, meta-analysis could not be performed and trials were systematically assessed in a structured approach. Included soy isoflavone studies had numerous quality deficiencies and did not consistently show a reduction of flushes after treatment with soy isoflavones. Therefore, there is no conclusive evidence, but only some indication of a benefit of soy isoflavones on hot flush frequency or severity.
Jacobs
Anja
A
Department of Food Safety, Federal Institute for Risk Assessment, Berlin, Germany. anja.jacobs@bfr.bund.de
Wegewitz
Uta
U
Sommerfeld
Christine
C
Grossklaus
Rolf
R
Lampen
Alfonso
A
D005260:Female; D019833:Genistein / Q000627:therapeutic use; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use; D008593:Menopause; D010936:Plant Extracts / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013025:Glycine max
D007529:Isoflavones; D010936:Plant Extracts; D019833:Genistein